Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

Allen Moton, Gopal Krishna, Lei Ma, Edward O'Mara, Pratapa Prasad, James McLeod, Richard A Preston

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: To evaluate posaconazole pharmacokinetics in subjects with different degrees of hepatic impairment compared with matched healthy subjects. Research design and methods: A total of 37 subjects were enrolled in this open-label, single-dose, parallel-group study; 19 with hepatic impairment and 18 healthy subjects with matching demographics. Each subject received a single 400-mg oral dose of posaconazole after a high-fat meal. Blood samples for analysis were taken up to 648 h (4 weeks) postdose. Results: Compared with maximum plasma concentration (Cmax) values in matched subjects with normal hepatic function, values were higher among subjects with moderate hepatic impairment (517 vs. 724 ng/mL) but lower among subjects with severe hepatic impairment (608 vs. 403 ng/mL). No clear trend toward increased or decreased exposure was observed with increasingly severe hepatic impairment, and extensive overlap occurred between normal and hepatically impaired subjects. Therefore, pharmacokinetic variables Cmax and area under the curve from time 0 to the time of final quantifiable sample (AUCtf) values were pooled for subjects with hepatic impairment. Pooled Cmax values were similar to the pooled normal groups (607 vs. 605 ng/mL), whereas there was an overall 36% increase in exposure (AUCtf) for the pooled hepatic impairment group compared with the pooled normal group. Posaconazole was well-tolerated, with six (33%) healthy subjects and six (32%) hepatically impaired subjects reporting adverse events. Conclusions: The data from this small single-dose study suggest posaconazole is safe. Furthermore, although limited by the small number of subjects enrolled, the authors feel that dose adjustments are probably not necessary in patients with hepatic impairment; however, physicians should continue to monitor posaconazole use in patients with hepatic impairment.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalCurrent Medical Research and Opinion
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Suspensions
Pharmacokinetics
Liver
Healthy Volunteers
posaconazole
Area Under Curve
Meals
Research Design
Fats
Demography
Physicians

Keywords

  • Antifungal agents
  • Liver disease
  • Pharmacokinetics
  • Posaconazole
  • Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. / Moton, Allen; Krishna, Gopal; Ma, Lei; O'Mara, Edward; Prasad, Pratapa; McLeod, James; Preston, Richard A.

In: Current Medical Research and Opinion, Vol. 26, No. 1, 01.01.2010, p. 1-7.

Research output: Contribution to journalArticle

Moton, Allen ; Krishna, Gopal ; Ma, Lei ; O'Mara, Edward ; Prasad, Pratapa ; McLeod, James ; Preston, Richard A. / Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment. In: Current Medical Research and Opinion. 2010 ; Vol. 26, No. 1. pp. 1-7.
@article{1732142b3abd4596a0f461293ec9c0d4,
title = "Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment",
abstract = "Objective: To evaluate posaconazole pharmacokinetics in subjects with different degrees of hepatic impairment compared with matched healthy subjects. Research design and methods: A total of 37 subjects were enrolled in this open-label, single-dose, parallel-group study; 19 with hepatic impairment and 18 healthy subjects with matching demographics. Each subject received a single 400-mg oral dose of posaconazole after a high-fat meal. Blood samples for analysis were taken up to 648 h (4 weeks) postdose. Results: Compared with maximum plasma concentration (Cmax) values in matched subjects with normal hepatic function, values were higher among subjects with moderate hepatic impairment (517 vs. 724 ng/mL) but lower among subjects with severe hepatic impairment (608 vs. 403 ng/mL). No clear trend toward increased or decreased exposure was observed with increasingly severe hepatic impairment, and extensive overlap occurred between normal and hepatically impaired subjects. Therefore, pharmacokinetic variables Cmax and area under the curve from time 0 to the time of final quantifiable sample (AUCtf) values were pooled for subjects with hepatic impairment. Pooled Cmax values were similar to the pooled normal groups (607 vs. 605 ng/mL), whereas there was an overall 36{\%} increase in exposure (AUCtf) for the pooled hepatic impairment group compared with the pooled normal group. Posaconazole was well-tolerated, with six (33{\%}) healthy subjects and six (32{\%}) hepatically impaired subjects reporting adverse events. Conclusions: The data from this small single-dose study suggest posaconazole is safe. Furthermore, although limited by the small number of subjects enrolled, the authors feel that dose adjustments are probably not necessary in patients with hepatic impairment; however, physicians should continue to monitor posaconazole use in patients with hepatic impairment.",
keywords = "Antifungal agents, Liver disease, Pharmacokinetics, Posaconazole, Safety",
author = "Allen Moton and Gopal Krishna and Lei Ma and Edward O'Mara and Pratapa Prasad and James McLeod and Preston, {Richard A}",
year = "2010",
month = "1",
day = "1",
doi = "10.1185/03007990903364657",
language = "English",
volume = "26",
pages = "1--7",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

AU - Moton, Allen

AU - Krishna, Gopal

AU - Ma, Lei

AU - O'Mara, Edward

AU - Prasad, Pratapa

AU - McLeod, James

AU - Preston, Richard A

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: To evaluate posaconazole pharmacokinetics in subjects with different degrees of hepatic impairment compared with matched healthy subjects. Research design and methods: A total of 37 subjects were enrolled in this open-label, single-dose, parallel-group study; 19 with hepatic impairment and 18 healthy subjects with matching demographics. Each subject received a single 400-mg oral dose of posaconazole after a high-fat meal. Blood samples for analysis were taken up to 648 h (4 weeks) postdose. Results: Compared with maximum plasma concentration (Cmax) values in matched subjects with normal hepatic function, values were higher among subjects with moderate hepatic impairment (517 vs. 724 ng/mL) but lower among subjects with severe hepatic impairment (608 vs. 403 ng/mL). No clear trend toward increased or decreased exposure was observed with increasingly severe hepatic impairment, and extensive overlap occurred between normal and hepatically impaired subjects. Therefore, pharmacokinetic variables Cmax and area under the curve from time 0 to the time of final quantifiable sample (AUCtf) values were pooled for subjects with hepatic impairment. Pooled Cmax values were similar to the pooled normal groups (607 vs. 605 ng/mL), whereas there was an overall 36% increase in exposure (AUCtf) for the pooled hepatic impairment group compared with the pooled normal group. Posaconazole was well-tolerated, with six (33%) healthy subjects and six (32%) hepatically impaired subjects reporting adverse events. Conclusions: The data from this small single-dose study suggest posaconazole is safe. Furthermore, although limited by the small number of subjects enrolled, the authors feel that dose adjustments are probably not necessary in patients with hepatic impairment; however, physicians should continue to monitor posaconazole use in patients with hepatic impairment.

AB - Objective: To evaluate posaconazole pharmacokinetics in subjects with different degrees of hepatic impairment compared with matched healthy subjects. Research design and methods: A total of 37 subjects were enrolled in this open-label, single-dose, parallel-group study; 19 with hepatic impairment and 18 healthy subjects with matching demographics. Each subject received a single 400-mg oral dose of posaconazole after a high-fat meal. Blood samples for analysis were taken up to 648 h (4 weeks) postdose. Results: Compared with maximum plasma concentration (Cmax) values in matched subjects with normal hepatic function, values were higher among subjects with moderate hepatic impairment (517 vs. 724 ng/mL) but lower among subjects with severe hepatic impairment (608 vs. 403 ng/mL). No clear trend toward increased or decreased exposure was observed with increasingly severe hepatic impairment, and extensive overlap occurred between normal and hepatically impaired subjects. Therefore, pharmacokinetic variables Cmax and area under the curve from time 0 to the time of final quantifiable sample (AUCtf) values were pooled for subjects with hepatic impairment. Pooled Cmax values were similar to the pooled normal groups (607 vs. 605 ng/mL), whereas there was an overall 36% increase in exposure (AUCtf) for the pooled hepatic impairment group compared with the pooled normal group. Posaconazole was well-tolerated, with six (33%) healthy subjects and six (32%) hepatically impaired subjects reporting adverse events. Conclusions: The data from this small single-dose study suggest posaconazole is safe. Furthermore, although limited by the small number of subjects enrolled, the authors feel that dose adjustments are probably not necessary in patients with hepatic impairment; however, physicians should continue to monitor posaconazole use in patients with hepatic impairment.

KW - Antifungal agents

KW - Liver disease

KW - Pharmacokinetics

KW - Posaconazole

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77649201260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649201260&partnerID=8YFLogxK

U2 - 10.1185/03007990903364657

DO - 10.1185/03007990903364657

M3 - Article

C2 - 19886860

AN - SCOPUS:77649201260

VL - 26

SP - 1

EP - 7

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 1

ER -